Cadrenal Therapeutics Investor Relations Material

Cadrenal Therapeutics, Inc. is a biopharmaceutical company focused on the development of tecarfarin, an advanced oral anticoagulant. Tecarfarin is designed to prevent heart attacks, strokes, and deaths caused by blood clots, particularly in patients with rare cardiovascular conditions that require long-term anticoagulation therapy. These conditions include end-stage kidney disease (ESKD), atrial fibrillation, and complications related to left ventricular assist devices (LVADs). The company aims to address the limitations of existing anticoagulants like warfarin, offering a more stable and reliable treatment option through an alternative metabolic pathway. The company is headquartered in Ponte Vedra, Florida, and its shares are listed on the NASDAQ.